Evaluation of adverse effects of AstraZeneca COVID-19 vaccine after the first dose in Libyan adults: a cross-sectional study

On January 2021, cases affected by coronavirus epidemic are constantly increasing, Libyan Ministry of Health provides the vaccine to the people those who are most at risk. The purpose of this study was to assess and verify the adverse effects of the first dose of the AstraZeneca COVID-19 vaccine. The study conducted at the Aljmail city, west region of Libya. The study was cross-sectional study during the period of August 31 and November 5, 2021. The method involved 133 adult Libyan participants of both gender ageing more tha 18 years old. The preliminary data were 54.0% who developed post-vaccination symptoms. The participant's aged 60 years and more with chronic diseases were more likely to have adverse effects after receiving the first dose of vaccine. In conclusion, AstraZeneca vaccine was good and effective but this study indicates a need for a large and long period study to confirm the safety of the vaccine use in the adult people.